Your search for olanzapine returned 98 results

The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.

A list of systemic drugs that can cause photosensitivity, including the type of reactions.

A 35-year-old man presents to the dermatology clinic for evaluation of multiple erythematous papules and nodules affecting his chest, arms, and upper back.

The FDA has accepted for review the New Drug Application (NDA) for ALKS 3831 (Alkermes) for the treatment of schizophrenia and bipolar I disorder.

Successful smoking cessation involves a 2-pronged approach, since there are 2 components to smoking – physiological and behavioral, according to Nervana Elkhadragy, PharmD, MS, TTS, of Purdue University, College of Pharmacy, Indianapolis.

List of therapeutic drug classes that are associated with significant weight gain and changes in fat distribution (lipodystrophy) and metabolism.

The Food and Drug Administration (FDA)’s Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee voted in favor (14 yes, 2 no, 1 abstain) of the approval of esketamine nasal spray (Spravato; Janssen) for the treatment of adult patients with treatment-resistant depression (TRD).

Overall, 45 and 44% on amisulpride and olanzapine, respectively, achieved remission (P=.87). Twenty-eight of the 40 patients not in remission started clozapine; 28% of the 18 patients who completed treatment achieved remission.

The researchers found that from baseline to week 12, the dual-energy X-ray absorptiometry percentage total body fat increased by 1.18, 4.12, and 1.66% for risperidone, olanzapine, and aripiprazole, respectively, and was significantly greater for olanzapine than risperidone or aripiprazole.

Results showed there was a significant crude risk linked to continuing vs discontinuing certain antipsychotics and developing gestational diabetes; for quetiapine the risk was 7.1% vs 4.1% (adjusted relative risk [ARR] 1.28), respectively; among olanzapine users it was 12% vs 4.7% (ARR 1.61), respectively.